JP2022501338A5 - - Google Patents
Info
- Publication number
- JP2022501338A5 JP2022501338A5 JP2021514381A JP2021514381A JP2022501338A5 JP 2022501338 A5 JP2022501338 A5 JP 2022501338A5 JP 2021514381 A JP2021514381 A JP 2021514381A JP 2021514381 A JP2021514381 A JP 2021514381A JP 2022501338 A5 JP2022501338 A5 JP 2022501338A5
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- yloxy
- pyrimidine
- methylphenyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024120830A JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2025150799A JP2026009898A (ja) | 2018-09-18 | 2025-09-11 | 抗腫瘍剤としてのキナゾリン誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/106098 | 2018-09-18 | ||
| CN2018106098 | 2018-09-18 | ||
| CNPCT/CN2019/091078 | 2019-06-13 | ||
| CN2019091078 | 2019-06-13 | ||
| PCT/CN2019/106233 WO2020057511A1 (en) | 2018-09-18 | 2019-09-17 | Quinazoline derivatives as antitumor agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120830A Division JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501338A JP2022501338A (ja) | 2022-01-06 |
| JP2022501338A5 true JP2022501338A5 (OSRAM) | 2022-09-28 |
| JP7546550B2 JP7546550B2 (ja) | 2024-09-06 |
Family
ID=69888359
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514381A Active JP7546550B2 (ja) | 2018-09-18 | 2019-09-17 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2024120830A Withdrawn JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2025150799A Pending JP2026009898A (ja) | 2018-09-18 | 2025-09-11 | 抗腫瘍剤としてのキナゾリン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120830A Withdrawn JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2025150799A Pending JP2026009898A (ja) | 2018-09-18 | 2025-09-11 | 抗腫瘍剤としてのキナゾリン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11723908B2 (OSRAM) |
| EP (3) | EP4360713B1 (OSRAM) |
| JP (3) | JP7546550B2 (OSRAM) |
| KR (2) | KR102889933B1 (OSRAM) |
| CN (2) | CN112654612A (OSRAM) |
| AU (2) | AU2019341273B2 (OSRAM) |
| CA (1) | CA3099776A1 (OSRAM) |
| DK (2) | DK4360713T3 (OSRAM) |
| ES (2) | ES2971927T3 (OSRAM) |
| FI (2) | FI3853220T3 (OSRAM) |
| HR (2) | HRP20240293T1 (OSRAM) |
| HU (2) | HUE065578T2 (OSRAM) |
| LT (2) | LT4360713T (OSRAM) |
| PL (2) | PL4360713T3 (OSRAM) |
| PT (2) | PT4360713T (OSRAM) |
| RS (2) | RS66314B1 (OSRAM) |
| SI (2) | SI3853220T1 (OSRAM) |
| SM (1) | SMT202400524T1 (OSRAM) |
| WO (1) | WO2020057511A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| HUE065578T2 (hu) * | 2018-09-18 | 2024-06-28 | Hoffmann La Roche | Kinazolin-származékok, mint daganatellenes szerek |
| CN111377850B (zh) * | 2018-12-31 | 2022-10-18 | 艾琪康医药科技（上海）有限公司 | 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法 |
| TWI820414B (zh) * | 2020-04-17 | 2023-11-01 | 大陸商北京賽特明強醫藥科技有限公司 | 喹唑啉類化合物、製備方法及其應用 |
| CN113527215B (zh) * | 2020-04-17 | 2023-12-05 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| KR20230156767A (ko) * | 2021-03-19 | 2023-11-14 | 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 | 퀴나졸린계 화합물, 조성물 및 퀴나졸린계 화합물의 적용 |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN117858872A (zh) * | 2021-06-22 | 2024-04-09 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| WO2022271749A1 (en) * | 2021-06-22 | 2022-12-29 | Blueprint Medicines Corporation | Heterocyclic egfr inhibitors for use in the treatment of cancer |
| CN117940424A (zh) * | 2021-06-22 | 2024-04-26 | 缆图药品公司 | Egfr抑制剂 |
| CN117836286A (zh) * | 2021-06-22 | 2024-04-05 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| CN115894383B (zh) * | 2021-09-30 | 2025-12-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| MA66471B1 (fr) * | 2021-10-20 | 2026-02-27 | F. Hoffmann-La Roche Ag | Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation |
| WO2023138675A1 (zh) * | 2022-01-21 | 2023-07-27 | 默达药物（香港）有限公司 | 喹啉化合物及其用途 |
| US20230293539A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof |
| JP2025509995A (ja) * | 2022-03-28 | 2025-04-11 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 含窒素複素環系化合物、その調製方法及びその医薬的使用 |
| CN115650977A (zh) * | 2022-10-09 | 2023-01-31 | 广东润兴生物科技有限公司 | 一种妥卡替尼的合成方法 |
| TW202446386A (zh) * | 2023-04-14 | 2024-12-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 喹唑啉ＥｒｂＢ抑制劑的藥物形式 |
| WO2024249642A1 (en) * | 2023-06-02 | 2024-12-05 | Acerand Therapeutics (Hong Kong) Limited | Egfr inhibitors |
| AU2024353411A1 (en) * | 2023-09-27 | 2026-05-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof |
| WO2025195333A1 (en) | 2024-03-19 | 2025-09-25 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation of erbb2 inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0171407B1 (en) | 1984-01-30 | 1993-11-18 | Imperial Cancer Research Technology Limited | Improvements relating to growth factors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| EP0494135B1 (en) | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| NZ522568A (en) | 2000-06-22 | 2004-12-24 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| JP2005515176A (ja) | 2001-11-03 | 2005-05-26 | アストラゼネカ アクチボラグ | 抗腫瘍剤としてのキナゾリン誘導体 |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2004000529A1 (de) | 2002-06-24 | 2003-12-31 | Fagerdala Deutschland Gmbh | Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP4828421B2 (ja) | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| CA2755268C (en) * | 2005-11-15 | 2013-12-31 | Array Biopharma, Inc. | Erbb inhibitors |
| BRPI0720169A2 (pt) | 2006-12-12 | 2013-12-24 | Takeda Pharmaceutical | Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto |
| WO2017148391A1 (zh) * | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| EP3516071B1 (en) | 2016-09-22 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
| CN109422755B (zh) * | 2017-09-01 | 2023-07-04 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| WO2019120213A1 (zh) | 2017-12-19 | 2019-06-27 | 南京明德新药研发股份有限公司 | 喹唑啉衍生物及其应用 |
| US12030897B2 (en) | 2018-05-08 | 2024-07-09 | Medshine Discovery Inc. | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof |
| AR117424A1 (es) * | 2018-05-08 | 2021-08-04 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de los receptores erbb |
| HUE065578T2 (hu) * | 2018-09-18 | 2024-06-28 | Hoffmann La Roche | Kinazolin-származékok, mint daganatellenes szerek |
-
2019
- 2019-09-17 HU HUE19862146A patent/HUE065578T2/hu unknown
- 2019-09-17 US US17/051,176 patent/US11723908B2/en active Active
- 2019-09-17 PT PT232193573T patent/PT4360713T/pt unknown
- 2019-09-17 PL PL23219357.3T patent/PL4360713T3/pl unknown
- 2019-09-17 KR KR1020217003251A patent/KR102889933B1/ko active Active
- 2019-09-17 FI FIEP19862146.8T patent/FI3853220T3/fi active
- 2019-09-17 ES ES19862146T patent/ES2971927T3/es active Active
- 2019-09-17 HR HRP20240293TT patent/HRP20240293T1/hr unknown
- 2019-09-17 DK DK23219357.3T patent/DK4360713T3/da active
- 2019-09-17 CN CN201980044137.8A patent/CN112654612A/zh active Pending
- 2019-09-17 RS RS20241396A patent/RS66314B1/sr unknown
- 2019-09-17 PT PT198621468T patent/PT3853220T/pt unknown
- 2019-09-17 KR KR1020257038595A patent/KR20250171398A/ko active Pending
- 2019-09-17 EP EP23219357.3A patent/EP4360713B1/en active Active
- 2019-09-17 HU HUE23219357A patent/HUE069764T2/hu unknown
- 2019-09-17 AU AU2019341273A patent/AU2019341273B2/en active Active
- 2019-09-17 SM SM20240524T patent/SMT202400524T1/it unknown
- 2019-09-17 HR HRP20241743TT patent/HRP20241743T1/hr unknown
- 2019-09-17 ES ES23219357T patent/ES3007082T3/es active Active
- 2019-09-17 LT LTEP23219357.3T patent/LT4360713T/lt unknown
- 2019-09-17 CN CN202410230537.0A patent/CN118255772A/zh active Pending
- 2019-09-17 FI FIEP23219357.3T patent/FI4360713T3/fi active
- 2019-09-17 LT LTEPPCT/CN2019/106233T patent/LT3853220T/lt unknown
- 2019-09-17 EP EP24208940.7A patent/EP4523755A3/en active Pending
- 2019-09-17 RS RS20240267A patent/RS65413B1/sr unknown
- 2019-09-17 SI SI201930718T patent/SI3853220T1/sl unknown
- 2019-09-17 EP EP19862146.8A patent/EP3853220B1/en active Active
- 2019-09-17 JP JP2021514381A patent/JP7546550B2/ja active Active
- 2019-09-17 DK DK19862146.8T patent/DK3853220T3/da active
- 2019-09-17 PL PL19862146.8T patent/PL3853220T3/pl unknown
- 2019-09-17 CA CA3099776A patent/CA3099776A1/en active Pending
- 2019-09-17 SI SI201930872T patent/SI4360713T1/sl unknown
- 2019-09-17 WO PCT/CN2019/106233 patent/WO2020057511A1/en not_active Ceased
-
2023
- 2023-05-18 US US18/319,509 patent/US20230293533A1/en active Pending
-
2024
- 2024-07-15 AU AU2024204847A patent/AU2024204847A1/en active Pending
- 2024-07-26 JP JP2024120830A patent/JP2024164018A/ja not_active Withdrawn
-
2025
- 2025-09-11 JP JP2025150799A patent/JP2026009898A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240293T1 (hr) | Derivati kinazolina kao protutumorska sredstva | |
| US12486290B2 (en) | Isoindolinone and indazole compounds for the degradation of EGFR | |
| ES2377849T3 (es) | Compuestos amino-heterocíclicos | |
| JP2024510606A5 (OSRAM) | ||
| JP6537527B2 (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| JP2025003975A (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| JP6585158B2 (ja) | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 | |
| DK2864295T3 (en) | Hitherto UNKNOWN 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ON AND THIS1,2,3,4-TETRAHYDROPYRIMIDO {1,2-A} PYRIMIDIN-6 SUBSTITUTES INCLUDING A SUBSTITUTE MORPHOLIN, PREPARATION AND PHARMACEUTICAL APPLICATION THEREOF | |
| JP2019517596A5 (OSRAM) | ||
| JP2014528433A5 (OSRAM) | ||
| JP2019505541A5 (OSRAM) | ||
| US11319324B2 (en) | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | |
| CN102762208A (zh) | 作为ck2抑制剂的吡唑嘧啶和相关杂环 | |
| CN107667092B (zh) | 作为fgfr4抑制剂的甲酰化n-杂环衍生物 | |
| JP2017511365A5 (OSRAM) | ||
| US20160045505A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| HRP20241222T1 (hr) | Makrociklički spojevi kao agonisti sting, te postupci i njihova upotreba | |
| US20240158418A1 (en) | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | |
| JP2020526549A5 (OSRAM) | ||
| NZ728122A (en) | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors | |
| WO2017157792A1 (en) | Combinations of copanlisib | |
| JP2014503590A5 (OSRAM) | ||
| JP2025528766A (ja) | Ｈｅｒ２を調節するための化合物および方法 | |
| CN113332292A (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 | |
| US20210179557A1 (en) | Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same |